WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. Fundamental Analysis
WuXi Biologics (Cayman) Inc. (WXIBF) shows moderate financial fundamentals with a PE ratio of 35.81, profit margin of 20.92%, and ROE of 9.67%. The company generates $19.5B in annual revenue with moderate year-over-year growth of 9.63%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze WXIBF's fundamental strength across five key dimensions:
Efficiency Score
WeakWXIBF struggles to generate sufficient returns from assets.
Valuation Score
ModerateWXIBF shows balanced valuation metrics.
Growth Score
ModerateWXIBF shows steady but slowing expansion.
Financial Health Score
ExcellentWXIBF maintains a strong and stable balance sheet.
Profitability Score
ModerateWXIBF maintains healthy but balanced margins.
Key Financial Metrics
Is WXIBF Expensive or Cheap?
P/E Ratio
WXIBF trades at 35.81 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, WXIBF's PEG of 0.18 indicates potential undervaluation.
Price to Book
The market values WuXi Biologics (Cayman) Inc. at 3.34 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 20.21 times EBITDA. This signals the market has high growth expectations.
How Well Does WXIBF Make Money?
Net Profit Margin
For every $100 in sales, WuXi Biologics (Cayman) Inc. keeps $20.92 as profit after all expenses.
Operating Margin
Core operations generate 29.31 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.67 in profit for every $100 of shareholder equity.
ROA
WuXi Biologics (Cayman) Inc. generates $6.94 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
WuXi Biologics (Cayman) Inc. generates strong operating cash flow of $5.57B, reflecting robust business health.
Free Cash Flow
WuXi Biologics (Cayman) Inc. produces free cash flow of $1.71B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.41 in free cash annually.
FCF Yield
WXIBF converts 1.20% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
35.81
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.34
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.11
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.88
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How WXIBF Stacks Against Its Sector Peers
| Metric | WXIBF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 35.81 | 29.45 | Worse (Expensive) |
| ROE | 9.67% | 779.00% | Weak |
| Net Margin | 20.92% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.11 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 2.88 | 4.65 | Strong Liquidity |
| ROA | 6.94% | -19344.00% (disorted) | Weak |
WXIBF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews WuXi Biologics (Cayman) Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
359.04%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
224.15%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
322.87%
Industry Style: Defensive, Growth, Innovation
High Growth